טוען...
Different outcomes for relapsed vs. refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG)
BACKGROUND: (131)I-metaiodobenzylguanidine ((131)I-MIBG) is a targeted radiopharmaceutical with significant activity in high-risk relapsed and chemotherapy-refractory neuroblastoma. Our primary aim was to determine if there are differences in response rates to (131)I-MIBG between patients with relap...
שמור ב:
| הוצא לאור ב: | Eur J Cancer |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4607645/ https://ncbi.nlm.nih.gov/pubmed/26254811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2015.07.023 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|